Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564145 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
A Phase 3 study, sponsored by Sol-Gel Technologies.
- Terminated
- Registry status
- Phase 3
- Development phase
- 547
- Enrollment target
NCT03564145 is a Phase 3 study that was terminated before completion, run by Sol-Gel Technologies. The registered enrollment target is 547 participants.
The verdict
NCT03564145, a Phase 3 study, was terminated before completion, sponsored by Sol-Gel Technologies.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 547 participants
- Enrollment target
Study Summary
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
Interventions
- DRUG S5G4T-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03564145
The ClinicalTrials.gov registry entry for NCT03564145 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which S5G4T-1 is the first listed.
NCT03564145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03564145 about?
NCT03564145 is a clinical study titled "A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea". To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
What is the current status of trial NCT03564145?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 547 participants. The study started on 2018-09-12. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT03564145?
The interventions under investigation include: S5G4T-1 (DRUG).
Who is sponsoring clinical trial NCT03564145?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.